Immunogenomics combines the fields of immunology (study of the immune system) and genomics (study of the genetic changes in cancer). According to the proposal submitted for approval, researchers are just now uncovering the extent of immunogenetic diversity among human populations. Genetic diversity in immune genes significantly impacts individual immune responses, with critical implications for how people develop and administer novel vaccines and therapeutics, as well as characterize complex and dynamic immune responses in infection, autoimmune disease and cancer.

School of Medicine Interim Dean Jeffrey Bumpous said that the university is well-prepared to support this research with equipment that other research institutes do not have, and the new endowment will accelerate efforts to understand the rapidly expanding field of immunogenomics.

Funding for the endowment comes from the estate of Carolyn S. Browning ($934,498.15) and the estate of Clifford Ernst ($65,501.85). UofL will request the gifts be matched by a contribution of $1 million from the Commonwealth of Kentucky Research Challenge Trust Fund, resulting in a total contribution of $2 million.

Browning, the endowment’s namesake, was a longtime Louisville resident, teaching music and Spanish for more than 30 years. Her husband, Harold Alonzo Browning, Jr., was a city editor for the Louisville Times. The Browning estate has provided gifts to other medical schools as well as the American Diabetes Association, memorial Sloan Kettering and St. Jude’s Children’s Research Hospital.

The work, recently published in the journal , reveals an underappreciated connection between genetics and our antibodies. Antibodies are key players in our immune system, with important roles in human health and disease, including in infection, autoimmunity, cancer and even vaccine responsiveness.

“Our work demonstrates that not everyone has the same capacity to generate certain types of antibodies due to genetics,” said Oscar Rodriguez, a post-doctoral fellow at UofL, and the first author of the study. “This could have critical implications for how we assess outcomes related to treatments and vaccines that depend on the antibody response.”

Vaccines, for example, work by simulating a viral infection and triggering an immune response — a sort of drill that teaches the body what a virus looks like and how to fight it. While it’s commonly known that individual response to vaccines can vary from person to person, this work shows more clearly than ever that these variations may depend on the antibody genes a person has inherited.

“For a long time, we’ve assumed vaccines could be designed using a one-size-fits-all approach,” said Melissa Smith, director of the , and lead author of the study. “This research shows that genetics predisposes us to qualitatively and quantitatively different antibody responses. If this information could be used to understand when individuals will or won’t respond to a given vaccine or treatment, that could be hugely impactful.”

The research also revealed that differences in our antibody responses could be linked to broader patterns of genetic diversity across human populations. This stresses the need to better characterize diversity in the genes that encode antibodies, and specifically increase the sampling of understudied populations. This is one of the driving forces behind research being conducted by this team.

Critical for advancing this effort is the recent acquisition of a by the Sequencing Technology Center. UofL is one of only a handful of service providers in the country to offer access to this technology. Its use by this team could help improve our understanding of ancestry-specific immune gene-associated disease through the characterization of antibody genes in thousands of individuals worldwide, leading to improved and more equitable patient care. 

“We are currently building the most comprehensive catalogs of human antibody genetic variation from diverse genetic ancestries,” said Corey T. Watson, associate professor in the , and senior author of the study. “By studying a greater number of populations across the globe, we will be able to clarify the contribution genes make in positioning our immune systems to respond in a variety of disease contexts, and hopefully inform next-generation treatments.”

Snyder’s talk, “Big Data and Health,” will take place at noon in room 101-102 at the Kosair Charities Clinical & Translational Research Building, 505 S. Hancock St. Snyder will focus on how information in large databases, or big data, can be used to develop improved and more individualized approaches to predicting, diagnosing and treating common diseases. 

, PhD, is an international leader in the fields of functional genomics and proteomics and is the director of the Center of Genomics and Personalized Medicine at Stanford University, where he is the Stanford W. Ascherman Professor and Chair of Genetics.

He wrote “Genomics & Personalized Medicine: What Everyone Needs to Know,” a book that explores the prospects and realities of genomics and personalized medicine for consumers. He was a key participant in the Encyclopedia of DNA Elements (ENCODE) project, which identified functional elements in the human genome.

Snyder’s research group was the first to perform a large-scale functional genomics project in any organism. Genomics is a branch of molecular biology that focuses on the structure, function, evolution and mapping of genomes in an organism’s complete set of DNA.

 has made several groundbreaking findings, including the discovery that much more of the human genome is either transcribed or contains regulatory elements than previously known, and that a high diversity of binding of transcription factors – gene products that participate in regulating what genes are active – occurs between and within species.

Snyder also has combined different advanced “omics” technologies to perform the first longitudinal Integrative Personal Omics Profile (iPOP) of an individual and used the information to assess disease risk and monitor disease states for personalized medicine. He co-founded several biotechnology companies, including Protometrix (now part of Life Technologies), Affomix (now part of Illumina), Excelix, Personalis and Q Bio.

Snyder received his PhD at the California Institute of Technology and postdoctoral training at Stanford University.

The lecture is sponsored by the  at the UofL School of Medicine. For more information, contact Janice Ellwanger at 502-852-5217 or David Samuelson at 502-852-7797.